Fedora Pharmaceuticals
Fedora Pharmaceuticals Inc. is dedicated to the discovery and development of novel antimicrobial drug candidates to address antimicrobial resistance (AMR). The company focuses on developing beta-lactamase inhibitors and other antimicrobial agents, with a pipeline of product candidates aimed at combating multi-drug resistant pathogens. Founded in 2011 and headquartered in Edmonton, Alberta, Canada, Fedora collaborates with industry and academia, and has achieved significant milestones including licensing agreements with Roche and Meiji Seika Pharma.
Industries
Nr. of Employees
small (1-50)
Fedora Pharmaceuticals
Products
Nacubactam (beta-lactamase inhibitor)
A beta-lactamase inhibitor candidate that inhibits multiple beta-lactamase enzymes and certain bacterial cell wall enzymes; developed for use in combination with beta-lactam antibiotics. Reported to have completed non-clinical studies, Phase I clinical evaluations, and pharmacokinetic assessments including in renal impairment and cUTI patients; described as ready for later-stage clinical development.
Nacubactam
A broad-spectrum beta-lactamase inhibitor from the diazabicyclooctane (DBO) class with a distinct dual mechanism of action, used in combination with cefepime or aztreonam to restore coverage against serious drug-resistant infections.
FPI-2119
A first-in-class, non-beta-lactam penicillin-binding protein (PBP) inhibitor derived from the lactivicin family of natural products with broad-spectrum activity against multidrug-resistant Gram-negative pathogens.
Nacubactam (beta-lactamase inhibitor)
A beta-lactamase inhibitor candidate that inhibits multiple beta-lactamase enzymes and certain bacterial cell wall enzymes; developed for use in combination with beta-lactam antibiotics. Reported to have completed non-clinical studies, Phase I clinical evaluations, and pharmacokinetic assessments including in renal impairment and cUTI patients; described as ready for later-stage clinical development.
Nacubactam
A broad-spectrum beta-lactamase inhibitor from the diazabicyclooctane (DBO) class with a distinct dual mechanism of action, used in combination with cefepime or aztreonam to restore coverage against serious drug-resistant infections.
FPI-2119
A first-in-class, non-beta-lactam penicillin-binding protein (PBP) inhibitor derived from the lactivicin family of natural products with broad-spectrum activity against multidrug-resistant Gram-negative pathogens.
Services
Negotiation and execution of licensing and collaboration agreements to advance antimicrobial candidates through clinical development and commercialization with industry partners.
Negotiation and execution of licensing and collaboration agreements to advance antimicrobial candidates through clinical development and commercialization with industry partners.
Expertise Areas
- Antimicrobial drug discovery
- Beta-lactamase inhibitor development
- Preclinical lead optimization
- In vitro microbiology and synergy testing
Key Technologies
- Beta-lactamase inhibitor chemistry
- Combination antibiotic development
- In vitro susceptibility and synergy assays (MIC, combination testing)
- Murine infection models
News & Updates
Fedora Pharmaceuticals Receives Alberta Life Sciences 'Company of the Year' Award
Fedora Pharmaceuticals was named 'Company of the Year' by BioAlberta in 2015, recognizing its achievements in life sciences and its historic licensing deal with Roche.
Fedora Pharmaceuticals Receives Support from the Government of Canada to Battle AMR
In 2017, Fedora received nonrefundable financial contribution from the National Research Council of Canada’s NRC-IRAP to develop a pipeline of antimicrobial product candidates.
Leading Industry and Research Groups Launch Coalition Against AMR Resistance
In 2020, industry and research organizations, including Fedora, launched the Canadian Antimicrobial Innovation Coalition to accelerate Canada's response to antimicrobial resistance.
Alberta Life Sciences 'Company of the Year' Award
Recognized in 2015 for significant achievement within Alberta's marketplace and business community.
ASTech Foundation’s Award for Outstanding Commercial Achievement
Received in 2015 for commercial success in the life sciences sector.
Fedora Pharmaceuticals Receives Alberta Life Sciences 'Company of the Year' Award
Fedora Pharmaceuticals was named 'Company of the Year' by BioAlberta in 2015, recognizing its achievements in life sciences and its historic licensing deal with Roche.
Fedora Pharmaceuticals Receives Support from the Government of Canada to Battle AMR
In 2017, Fedora received nonrefundable financial contribution from the National Research Council of Canada’s NRC-IRAP to develop a pipeline of antimicrobial product candidates.
Leading Industry and Research Groups Launch Coalition Against AMR Resistance
In 2020, industry and research organizations, including Fedora, launched the Canadian Antimicrobial Innovation Coalition to accelerate Canada's response to antimicrobial resistance.
Alberta Life Sciences 'Company of the Year' Award
Recognized in 2015 for significant achievement within Alberta's marketplace and business community.
ASTech Foundation’s Award for Outstanding Commercial Achievement
Received in 2015 for commercial success in the life sciences sector.